563 articles with Evotec AG
Evotec SE officially launched the construction of its J.POD ® biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France.
Boehringer, Evotec and bioMérieux found Aurobac to combat antimicrobial resistance, Turnstone and Moffitt Expand TIL Collab, Skyhawk to gain potential $2B from Sanofi RNA splicing deal.
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance
Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed.
Evotec SE has inked a deal with Janssen Pharmaceutical hat showcases its end-to-end integrated drug discovery and development platform.
Evotec SE announced that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Sernova shared positive Phase I/II data from an ongoing clinical study of its implantable Cell Pouch device that showed evidence of in vivo active insulin production.
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price of € 23 m.
Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.
Evotec SE and Almirall S.A., a global biopharmaceutical company focused on skin health, announced a multi-target alliance in Medical Dermatology.
Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes
Evotec SE and Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics announced a partnership in the field of diabetes.
Evotec SE announces that the Company has extended and expanded its partnership with Bristol Myers Squibb in targeted protein degradation, originally signed in 2018.
Bristol Myers Squibb announced it is extending and expanding its strategic partnership with Evotec in targeted protein degradation, marking its second protein degradation deal this month.
Evotec SE will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022.
Evotec SE reported financial results and corporate updates for the fiscal year ended 31 December 2021.
Evotec SE announced that the Company has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb triggering a payment of US$ 16 m to Evotec.
Evotec SE will announce its financial results for 2021 on Tuesday, 12 April 2022.
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
Evotec SE announced that the Company received a € 3 m milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into Phase II clinical development as a potential treatment for diabetic neuropathic pain.
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
Evotec SE presents at its virtual Capital Markets Day how artificial intelligence and machine learning enabled precision technologies in discovery and development processes are driving up Probability of Success, i.e. an increasing rate of approvals in the long-run.